OptimizeRx (NASDAQ:OPRX) Upgraded at B. Riley

B. Riley upgraded shares of OptimizeRx (NASDAQ:OPRX - Free Report) to a strong-buy rating in a report published on Wednesday morning, Marketbeat.com reports.

Several other analysts have also recently commented on the stock. Royal Bank of Canada reissued a "sector perform" rating and set a $6.00 price target (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Barclays decreased their price target on shares of OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Thursday, November 14th. Stifel Nicolaus reduced their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. William Blair reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Thursday, November 14th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, OptimizeRx presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.06.

OptimizeRx Price Performance

NASDAQ:OPRX traded up $0.62 on Wednesday, reaching $7.77. The stock had a trading volume of 1,071,350 shares, compared to its average volume of 250,070. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $14.13. The stock has a fifty day moving average price of $5.53 and a 200-day moving average price of $5.91. The company has a market capitalization of $143.13 million, a P/E ratio of -5.84 and a beta of 1.31. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Remove Ads

Institutional Investors Weigh In On OptimizeRx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Whetstone Capital Advisors LLC acquired a new stake in OptimizeRx in the 4th quarter valued at $6,563,000. Royce & Associates LP acquired a new stake in OptimizeRx in the 4th quarter valued at $5,198,000. Kennedy Capital Management LLC increased its stake in OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock valued at $2,887,000 after buying an additional 217,676 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock valued at $2,159,000 after buying an additional 39,740 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in OptimizeRx by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock valued at $1,948,000 after buying an additional 4,821 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.